Peer-reviewed veterinary case report
Carboplatin chemo after anal sac cancer surgery in dogs
By Wouda, R M et al.·Published in Veterinary and comparative oncology·2016·Department of Medical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of adjuvant carboplatin chemotherapy in the management of surgically excised anal sac apocrine gland adenocarcinoma in dogs.
- Species:
- dog
Plain-English summary
A group of 74 dogs with anal sac apocrine gland adenocarcinoma (a type of cancer) underwent surgery to remove the tumor. After surgery, 44 of the dogs received a chemotherapy drug called carboplatin, while 30 did not. The dogs that received carboplatin tolerated it well, and while the difference in survival times between the two groups wasn't statistically significant, treatment for any disease progression helped extend their lives. Overall, this suggests that carboplatin may be a helpful option for managing this type of cancer in dogs after surgery.
People also search for: dog anal sac cancer treatment · carboplatin for dogs · anal gland tumor surgery recovery
Abstract
There is no widely accepted standard of care for canine anal sac apocrine gland adenocarcinoma (ASAGAC). Surgery alone is inadequate in many cases, but the benefit of adjuvant chemotherapy is not well established. The primary objective of this retrospective study was to evaluate the role of carboplatin chemotherapy in the post-operative management of ASAGAC. Seventy-four dogs with naturally occurring ASAGAC underwent surgery. Forty-four dogs received adjuvant carboplatin and 30 did not. Median overall survival (OS) was 703 days. Median time to progression (TTP) was 384 days. Only primary tumour size and lymph node metastasis at diagnosis significantly impacted the outcome. Differences in OS and TTP, between the dogs that received adjuvant carboplatin and those that did not, failed to reach statistical significance. Treatment of progressive disease, whilst not limited to chemotherapy, significantly prolonged the survival. This study shows that adjuvant carboplatin chemotherapy is well tolerated and may have a role in the management of dogs with ASAGAC.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/26811974/